Taking statins for a long time may cause the liver to make more sugar, which can raise blood sugar levels.
Scientific Claim
Chronic statin treatment increases the expression of hepatic gluconeogenic enzymes G6PC and PCK1 and elevates hepatic glucose output in animal and human liver cell models, contributing to elevated blood glucose levels.
Original Statement
“statins significantly increase the expression of key gluconeogenic enzymes (such as G6PC [glucose-6-phosphatase] and PCK1 (phosphoenolpyruvate carboxykinase 1 [soluble]) in vitro and in vivo and promote hepatic glucose output.”
Evidence Quality Assessment
Claim Status
overstated
Study Design Support
Design cannot support claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
Based on abstract only - full methodology not available to verify. The study is preclinical (animal and in vitro), so definitive claims about causation or human relevance are unsupported. 'Increases' implies direct causation, but only association can be inferred.
More Accurate Statement
“Chronic statin treatment is associated with increased expression of hepatic gluconeogenic enzymes G6PC and PCK1 and elevated hepatic glucose output in animal and human liver cell models.”
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aWhether chronic statin use is consistently associated with increased hepatic glucose production and fasting glucose in humans across diverse populations.
Whether chronic statin use is consistently associated with increased hepatic glucose production and fasting glucose in humans across diverse populations.
What This Would Prove
Whether chronic statin use is consistently associated with increased hepatic glucose production and fasting glucose in humans across diverse populations.
Ideal Study Design
A meta-analysis of 20+ randomized controlled trials (n>10,000 total participants) comparing statin vs placebo in adults aged 40-75 with no diabetes at baseline, measuring fasting glucose, HOMA-IR, and liver enzyme expression via biopsy or imaging biomarkers over 2+ years.
Limitation: Cannot establish direct causation between autophagy and glucose output in humans.
Randomized Controlled TrialLevel 1bWhether statin therapy directly causes increased hepatic glucose output in humans compared to placebo.
Whether statin therapy directly causes increased hepatic glucose output in humans compared to placebo.
What This Would Prove
Whether statin therapy directly causes increased hepatic glucose output in humans compared to placebo.
Ideal Study Design
A double-blind RCT of 150 adults with prediabetes, randomized to atorvastatin 40mg/day vs placebo for 6 months, with primary outcomes of hepatic glucose production measured by stable isotope tracer and liver G6PC/PCK1 mRNA via biopsy.
Limitation: Ethical and practical limitations prevent liver biopsies in large populations.
Prospective Cohort StudyLevel 2bWhether long-term statin use predicts rising hepatic glucose output and incident diabetes in real-world populations.
Whether long-term statin use predicts rising hepatic glucose output and incident diabetes in real-world populations.
What This Would Prove
Whether long-term statin use predicts rising hepatic glucose output and incident diabetes in real-world populations.
Ideal Study Design
A prospective cohort of 5,000 statin-naïve adults aged 50-65 followed for 5 years, with annual measurements of fasting glucose, HOMA-IR, and liver fat (MRI-PDFF), stratified by statin use and dose.
Limitation: Cannot isolate autophagy as the mediating mechanism.
Animal StudyLevel 3In EvidenceWhether statin-induced autophagy is necessary and sufficient to drive hepatic gluconeogenesis in vivo.
Whether statin-induced autophagy is necessary and sufficient to drive hepatic gluconeogenesis in vivo.
What This Would Prove
Whether statin-induced autophagy is necessary and sufficient to drive hepatic gluconeogenesis in vivo.
Ideal Study Design
A study in diet-induced obese mice (n=8/group) comparing statin-treated wild-type vs ATG7-knockout or BECN1-heterozygous mice, measuring hepatic glucose output, autophagic flux, and gluconeogenic gene expression over 8 weeks.
Limitation: Findings cannot be directly generalized to humans.
In Vitro Cell StudyLevel 4In EvidenceWhether statins directly induce autophagy and gluconeogenic gene expression in human hepatocytes.
Whether statins directly induce autophagy and gluconeogenic gene expression in human hepatocytes.
What This Would Prove
Whether statins directly induce autophagy and gluconeogenic gene expression in human hepatocytes.
Ideal Study Design
A study using primary human hepatocytes treated with simvastatin (1–10 µM) for 24–72 hours, with and without autophagy inhibitors (chloroquine), measuring G6PC/PCK1 mRNA, protein, and glucose output.
Limitation: Lacks systemic metabolic context and immune/endocrine interactions.
Evidence from Studies
Supporting (1)
This study found that statins, the cholesterol-lowering drugs, make the liver produce more sugar by turning on specific genes (G6PC and PCK1), which can raise blood sugar levels — exactly what the claim says.